Emerging drugs for asthma

Expert Opinion on Emerging Drugs

Volumn 13, Issue 4, 2008, Pages 643-653

  Walsh, Garry M ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Airway inflammation; Asthma; Biopharmaceuticals; Corticosteroids

Indexed keywords

AEROVANT; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIMOSIAMOSE; CHEMOKINE; CHEMOKINE RECEPTOR CCR3; CICLESONIDE; CILOMILAST; CORTICOSTEROID; CYTOKINE; EOTAXIN; GLUCOCORTICOID; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMA638; MONOCYTE CHEMOTACTIC PROTEIN 4; OMALIZUMAB; PITRAKINRA; RANTES; ROFLUMILAST; SALBUTAMOL; STAT6 PROTEIN; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 344031; YM 355179; ZILEUTON;

ADD ON THERAPY; ADRENAL SUPPRESSION; ALLERGIC ASTHMA; ASTHMA; BONE DENSITY; BONE GROWTH; CARDIOTOXICITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; LEUKOCYTE; LIVER FUNCTION TEST; LOW DRUG DOSE; MEDIATOR RELEASE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CELL ADHESION MOLECULES; CYTOKINES; DRUGS, INVESTIGATIONAL; HUMANS; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 58149232415     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210802591378     Document Type: Review

References (63)

1. Berger WE. New approaches to managing asthma: a US perspective. Therap Clin Risk Management 2008;4:363-79
2. Holtzman MJ. Drug development for asthma. Am J Resp Cell Mol Biol 2003;29:163-71
3. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003;178:347-55
4. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63
5. Barnes PJ. New treatments for asthma. Eur J Int Med 2000;11:9-20
6. Ishimura M, Suda M, Morizumi K, et al. Effects of KP-496, a novel dual antagonist at the cysteinyl leukotriene receptor 1 and the thromboxane A2; receptor, on airway obstruction in guinea pigs. Br J Pharmacol 2008;153:669-75
7. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206
8. Kamath AV, Pavord ID, Ruparelia PR, et al. Is the neutrophil the key effector cell in severe asthma? Thorax 2005;60:529-30
9. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999;353:57-62
10. Dahlen SE. 5-lipoxygenase inhibitors. In: New Drugs for Asthma, Allergy and COPD. Hansel TT, Barnes PJ, editors. Basel: Karger, 2001. p. 115-20
11. Fox H. Anti-IgE in severe persistent allergic asthma. Respirology 2007;12(Suppl 3):S22-8
12. Milgrom H, Fick RB, Su J, et al .Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-73
13. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe asthma. J Allergy Clin Immunol 2001;108:184-90
14. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
15. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;23:76-81
16. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with Omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;23:76-81
17. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309
18. Chipps B, Buhl R, Beeh KM, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006;11:2201-8
19. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadidan rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide J Clin Endocrinol Metab 2002;87(5):2160-3
20. Taylor DA, Jensen MW Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999;160:237
21. Larsen BB, Nielsen LP, Engelstatter R, et al. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003;58:207
22. Gauvreau GM, Boulet LP, Postma DS, et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005;116:285
23. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma Allergy 2005;60:330
24. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94(6):557-752
25. Vayssiere BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo 1997;11(9):1245-55
26. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-70
27. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol 2000;47:127
28. Barnes PJ. New treatments for asthma. Eur J Int Med 2000;11:9-20
29. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008;155(3):288-90. Epub 2008 Jul 28
30. Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 1999;36:453-496
31. Egan RW, Umland SP, Cuss FM, Chapman RW. Biology of interleukin-5 and its relevance to allergic disease. Allergy 1996;51:71-81
32. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hypersonsiveness and the late asthmatic response. Lancet 2000;356:2144-8
33. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199
34. Kips JC, O'Conner BJ, Langley SJ, et al. Effect of SCH55700, a humanised anti-human interleukin-5 antibody in severe persistent asthma - a pilot study. Am J Resp Crit Care Med 2003;167:1655-9
35. Flood-Page P, Swenson C, Faiferman I, et al. International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71
36. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36
37. Rothenberg ME, Klion AD, Roufosse FE, et al. Mepolizumab HES Study GroupTreatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358(12):1215-28
38. Deshpande DA, Dogan S, Walseth TF, et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway. Am J Respir Cell Mol Biol 2004;31:36-42
39. Chiba Y, Nakazawa S, Todoroki M, et al. Misawa MInterleukin-13 Augments Bronchial Smooth Muscle Contractility with an Upregulation of RhoA Protein. Am J Respir Cell Mol Biol 2008 [Epub ahead of print]
40. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063-70
41. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:1816-23
42. Ma Y, Hayglass KT, Becker AB, et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 2007;62(6):675-82
43. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-60
44. Walsh GM. Targeting airway inflammation: novel therapies for the treatment of asthma. Current Medicinal Chemistry 2006;13:3105-11
45. Bree A, Schlerman FJ, Wadanoli M, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 2007;119(5):1251-7
46. O'Byrne PM, MD Inman, E Adelroth. Reassessing the Th2 cytokine basis of asthma, Trends Pharmacol Sci 2004;25:244-8
47. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370(9596):1422-31 • Excellent study demonstrating that dual targeting of IL-4 and Il-13 may represent an effective therapy for asthma.
48. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121:5-10
49. Rabinowitz MH, Andrews RC, Becherer JD, et al. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem 2001;44:425
50. Erin EM, Williams TJ, Barnes PJ, et al. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Inflamm Allergy 2002;1:201-14
51. De Lucca GV, Kim UT, Johnson C, et al. Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. J Med Chem 2002;45:3794-804
52. Suzuki K, Morokata T, Morihira K, et al. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. Biochem Biophys Res Commun 2006;339:1217-23
53. Morokata T, Suzuki K, Masunaga Y, et al. A novel, selective, and orally available antagonist for CC chemokine receptor 3. J Pharmacol Exp Ther 2006;317(1):244-50
54. Wegmann M, Göggel R, Sel S, et al. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. Am J Respir Cell Mol Biol 2007;36(1):61-7
55. Walsh GM, Robinson P, Wu P. Recent developments in targeting eosinophil Accumulation as a Novel Therapeutic Approach for Asthma. Open Allergy J 2008;1:35-41
56. Avila PC, Boushey HA, Wong H, et al. Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses. Clin Exp Allergy 2004;34:77-84
57. Beeh KM, Beier J, Meyer M, et al. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm Pharmacol Ther 2006;19(4):233-41
58. Chiba Y, Sato S, Misawa M. Inhibition of antigen-induced bronchial smooth muscle hyperresponsiveness by lovastatin in mice. J Smooth Muscle Res 2008;44(3-4):123-8
59. Woodside DG, Vanderslice P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs 2008;22(2):85-100 • Excellent review of the state of development of anti-inflammatory therapies based on adhesion molecule blockade.
60. Laufs U, Liao JK. Isoprenoid merabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003;5:372-8
61. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61:729-34 • Excellent review of the potential role of statins in respiratory diseases.
62. Walsh GM. Statins as Emerging treatments for asthma and COPD. Exp Rev Respir Med 2008;23:329-35
63. Menzies D, Menzies D, Nair A, et al. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007;119:328-35 •• Excellent, well-conducted randomised clinical trial demonstrating no positive effects following simvastatin treatment of patients with asthma.